[Featured Stock] Borak Rises Over 20% on Patent Ownership for Gastric Cancer Treatment Approved in China

Food and pharmaceutical company Borak saw a significant surge in its stock price on the 8th. Expectations for improved performance grew as it was revealed that the company holds patents related to the raw material of the orally administered stomach cancer treatment drug ‘Liporaxel,’ which received market approval in China.

As of 2:25 PM on the same day, Borak’s stock was trading at 1,234 KRW, up 21.82% from the previous closing price. The stock remained flat in the early trading hours but surged sharply after 11 AM. In the afternoon session, the stock price experienced increased volatility, repeatedly rising and adjusting.

According to industry sources, Borak holds patents related to the drug delivery system for ‘Paclitaxel,’ the raw material of Liporaxel. It was announced that Liporaxel, an oral formulation of Paclitaxel, received market approval from China’s National Medical Products Administration (NMPA) on the same day.

The global market size for the anticancer drug Paclitaxel is known to reach 5 trillion KRW. Daehwa Pharmaceutical developed Liporaxel by applying its own lipid-based self-emulsifying drug delivery system (DHLASED) platform technology.

A securities industry official analyzed, "The stock price rose sharply due to expectations of improved performance from Liporaxel," adding, "However, there is uncertainty about how much it will actually contribute to Borak’s earnings, which has increased stock price volatility."

This content was produced with the assistance of AI translation services.